Clinical trial
An Open-label, Randomized, Fed, Single-dose, 2-sequence, 4-period, Crossover Phase I Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 in Healthy Volunteers
NCT06744439 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Randomized, Fed, Single-dose, 2-sequence, 4-period, Crossover Phase I Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 in Healthy Volunteers
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 9, 2025
- Completion date
- March 16, 2025
- Enrollment
- 49 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.